Retinoic acid enhances sensitivity of neuroblastoma cells for imatinib mesylate

Pediatric Blood and Cancer

Volumn 55, Issue 3, 2010, Pages 464-470

  Neumann, Ingo ^a   Foell, Jürgen L ^a   Bremer, Marianne ^a   Volkmer, Ines ^a   Korholz, Dieter ^a   Burdach, Stefan ^b   Staege, Martin S ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Differentiation; Gene expression; Kinase inhibitors; Neuroblastoma; Retinoic acid

Indexed keywords

CYTOCHROME P450 26A1; CYTOCHROME P450 2B1; GLYCERALDEHYDE 3 PHOSPHATE; IMATINIB; MESSENGER RNA; RETINOIC ACID; SCATTER FACTOR; STEM CELL FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; CYTOCHROME P450; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; RETINOIC ACID 4 HYDROXYLASE; RETINOIC ACID 4-HYDROXYLASE;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE EXPRESSION; GENE SEQUENCE; HETEROZYGOSITY; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NEUROBLASTOMA CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION; CELL SURVIVAL; DRUG EFFECT; GENETICS; METABOLISM; NEUROBLASTOMA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CYTOCHROME P-450 ENZYME SYSTEM; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; MICROARRAY ANALYSIS; NEUROBLASTOMA; PIPERAZINES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRETINOIN; UP-REGULATION;

EID: 77955483313     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22603     Document Type: Article

References (38)

1. Spix C, Pastore G, Sankila R, et al. Neuroblastoma incidence and survival in European children (1978-1997): Report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006;42:2081-2091.
2. Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131- metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 2007;25:1054-1060.
3. Ricotti E, Fagioli F, Garelli E, et al. G. c-kit is expressed in soft tissue sarcoma of neuroectodermic origin and its ligand prevents apoptosis of neoplastic cells. Blood 1998;91:2397-2405.
4. Meco D, Riccardi A, Servidei T, et al. Antitumor activity of imatinib mesylate in neuroblastoma xenografts. Cancer Lett 2005;228:211-219.
5. Vitali R, Cesi V, Nicotra MR, et al. c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571. Int J Cancer 2003;106:147-152.
6. Te Kronnie G, Timeus F, Rinaldi A, et al. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition. Int J Mol Med 2004;14:373-382.
7. Bond M, Bernstein ML, Pappo A, et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study. Pediatr Blood Cancer 2008;50:254-258.
8. Germain P, Chambon P, Eichele G, et al. International Union of Pharmacology. LX. Retinoic acid receptors. Pharmacol Rev 2006;58:712-725.
9. Reynolds CP, Matthay KK, Villablanca JG, et al. Retinoid therapy of high-risk neuroblastoma. Cancer Lett 2003;197:185-192.
10. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-1173.
11. Children's Oncology Group (CCG 09709), Villablanca JG, Krailo MD, et al. Phase I trial of oral fenretinide in children with high-risk solid tumors: A report from the Children's Oncology Group (CCG 09709). J Clin Oncol 2006;24:3423-3430.
12. Adamson PC, Matthay KK, O'Brien M, et al. A phase 2 trial of all-trans-retinoic acid in combination with interferon-alpha2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group Study. Pediatr Blood Cancer 2007;49:661-665.
13. Armstrong JL, Redfern CP, Veal GJ. 13-cis retinoic acid and isomerisation in paediatric oncology - Is changing shape the key to success? Biochem Pharmacol 2005;69:1299-1306.
14. Blaner WS. Cellular metabolism and actions of 13-cis-retinoic acid. J Am Acad Dermatol 2001;45:S129-S135.
15. Armstrong JL, Taylor GA, Thomas HD, et al. Molecular targeting of retinoic acid metabolism in neuroblastoma: The role of the CYP26 inhibitor R116010 in vitro and in vivo. Br J Cancer 2007;96:1675-1683.
16. Armstrong JL, Ruiz M, Boddy AV, et al. Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells. Br J Cancer 2005;92:696-704.
17. Njar VC, Gediya L, Purushottamachar P, et al. Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. Bioorg Med Chem 2006;14:4323-4340.
18. Quere R, Baudet A, Cassinat B, et al. Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood 2007;109:4450-4460.
19. Biedler JL, Helson L, Spengler BA. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res 1973;33:2643-2652.
20. Tumilowicz JJ, Nichols WW, Cholon JJ, et al. Definition of a continuous human cell line derived from neuroblastoma. Cancer Res 1970;30:2110-2118.
21. Schwab M, Alitalo K, Klempnauer KH, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983;305:245-248.
22. Staege MS, Hutter C, Neumann I, et al. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res 2004;64:8213-8221.
23. Staege MS, Hansen G, Baersch G, et al. Functional and molecular characterization of interleukin-2 transgenic Ewing tumor cells for in vivo immunotherapy. Pediatr Blood Cancer 2004;43:23-34.
24. Hoennscheidt C, Max D, Richter N, et al. Expression of CD4 on Epstein-Barr virus-immortalized B cells. Scand J Immunol 2009;70:216-225.
25. Staege MS, Gisch K, Reske-Kunz AB. Cytotoxic T cells with reciprocal antigenic peptide presentation function are not generally resistant to mutual lysis. Immunol Cell Biol 2003;81:266-274.
26. Crosier PS, Ricciardi ST, Hall LR, et al. Expression of isoforms of the human receptor tyrosine kinase c-kit in leukemic cell lines and acute myeloid leukemia. Blood 1993;82:1151-1158.
27. Lemura A, Tsai M, Ando A, et al. The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis. Am J Pathol 1994;144:321-328.
28. Hassan HT, Zander A. Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis. Acta Haematol 1996;95:257-262.
29. Korja M, Finne J, Salmi TT, et al. No GIST-type c-kit gain of function mutations in neuroblastic tumours. J Clin Pathol 2005;58:762-765.
30. Shimada A, Hirato J, Kuroiwa M, et al. Expression of KIT and PDGFR is associated with a good prognosis in neuroblastoma. Pediatr Blood Cancer 2008;50:213-217.
31. Foster R, Byrnes E, Meldrum C, et al. Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT. Br J Dermatol 2008;159:1160-1169.
32. Packer BR, Yeager M, Burdett L, et al. SNP500Cancer: A public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res 2006;34:D617-D621.
33. Caruana G, Cambareri AC, Ashman LK. Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts. Oncogene 1999;18:5573-5581.
34. Palmberg E, Johnsen JI, Paulsson J, et al. Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo. Int J Cancer 2009;124:1227-1234.
35. González I, Andreu EJ, Panizo A, et al. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. Clin Cancer Res 2004;10:751-761.
36. Scotlandi K, Manara MC, Strammiello R, et al. C-kit receptor expression in Ewing's sarcoma: Lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J Clin Oncol 2003;21:1952-1960.
37. Febbo PG, Thorner A, Rubin MA, et al. Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. Clin Cancer Res 2006;12:152-158.
38. Khan AA, Villablanca JG, Reynolds CP, et al. Pharmacokinetic studies of 13-cis-retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation. Cancer Chemother Pharmacol 1996;39:34-41.